VIROGIN BIOTECH CANADA LTD has a total of 30 patent applications. It decreased the IP activity by 76.0%. Its first patent ever was published in 2016. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and agriculture are NANJING KAEDI BIOTECH INC, DEISSEROTH ALBERT B and GLUCKSMANN MARIA ALEXANDRA.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | United States | 7 | |
#3 | WIPO (World Intellectual Property Organization) | 7 | |
#4 | China | 5 | |
#5 | Australia | 1 | |
#6 | Canada | 1 | |
#7 | Hong Kong | 1 | |
#8 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Agriculture |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Animal care |
# | Name | Total Patents |
---|---|---|
#1 | Jia William | 26 |
#2 | Bu Xuexian | 15 |
#3 | Chouljenko Dmitry | 13 |
#4 | Liu Guoyu | 11 |
#5 | Liu Xiaohu | 9 |
#6 | Lee I-Fang | 8 |
#7 | Delwar Zahid | 6 |
#8 | Murad Yanal M | 5 |
#9 | Chouljenko Dmitry V | 5 |
#10 | Ding Jun | 5 |
Publication | Filing date | Title |
---|---|---|
WO2021026275A1 | Genetically modified enterovirus vectors | |
WO2020113151A1 | Hsv vector with reduced neurotoxicity | |
EP3743084A2 | Recombinant viral vaccines | |
WO2019099947A1 | Targeting moiety-decorated oncolytic viruses | |
TW201925219A | Compositions and methods for inhibiting CD279 interactions providing isolated or purified peptides for preventing or ameliorating the effects of cancer | |
EP3490583A1 | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules | |
CN109641020A | There is the hsv vector of enhancing duplication in cancer cell | |
CN109414487A | Utilize the composition and method of STAT1/3 inhibitor and oncolytic type herpesviral | |
US2018141975A1 | Compositions and methods for inhibiting CD279 interactions |